Drug Testing in the Workplace
description
Transcript of Drug Testing in the Workplace
![Page 1: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/1.jpg)
Drug Testing in the Workplace
Presented by Dr. Ramesh
Certified Medical Review Officer
Alliance Occupational Medicine
![Page 2: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/2.jpg)
Substance Abuse in the News
The largest oil spill in over 2 decades in the San Francisco Bay occurred due to substance abuse by the pilot, Capt. John Cota, of a cargo ship. The Cosco Busan's collision with a Bay Bridge tower in 2007 tore a 211-foot gash in the Hong Kong cargo ship, spilling bunker fuel. The Cosco Busan spill oiled 69 miles of shore, closed fisheries and killed more than 2,500 birds.
The NTSB concluded it was caused by Cota's "degraded cognitive performance from his use of impairing prescription medications.“
The National Transportation Safety Board found that Cota had a drunken driving conviction, a history of alcohol abuse and prescriptions for at least nine medications, including Valium; Vicodin; Zoloft for depression; Ativan, an anti-anxiety drug; Provigil for sleep disorders; Imitrex for migraines; and Darvon for pain.
![Page 3: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/3.jpg)
Substance Abuse In the News
The accident was the largest oil spill in the bay since 1988. The Cosco Busan's owner, Regal Stone Ltd., and its operator, Fleet Management Ltd., both of Hong Kong, agreed to pay $44 million to settle the civil case.
Capt. John Coto is currently trying to get his Mariner’s license back, however, the Coast Guard found that Cota "did not meet the medical standards and the professional qualifications requirements for renewal." They issued a final denial in Feb. 2012.
![Page 4: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/4.jpg)
Agenda
Substance Abuse Statistics
What is Reasonable Suspicion?
Signs and Symptoms of Substance Abuse
Components of a Drug Free Workplace Program
Specimen Testing and Confirmation
MRO Role in DOT Testing
Differences in DOT and non-DOT Testing
Alcohol Testing
Alternative Testing
Case Studies
![Page 5: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/5.jpg)
Substance Abuse Statistics
Prevalence of Illegal Drug Use
• Percent of persons 12 years of age and over with any illicit drug use in the past month: 8.7% (2009) and 8.9% (2010)
• Percent of persons 12 years of age and over with marijuana use in the past month: 6.6% (2009) and 6.9% (2010)
• Percent of persons 12 years of age and over with any non-medical use of a psychotherapeutic drug in the past month: 2.8% (2009) and 2.7% (2010)
Source: CDC
![Page 6: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/6.jpg)
Substance Abuse StatisticsResults from the 2010 National Survey on Drug Use and Health
Summary of Findings:
• 2010, Marijuana was the most commonly use illicit drug with 17.4 million current users.
Past month illicit drug use among persons aged 12 or older
![Page 7: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/7.jpg)
Substance Abuse Statistics
Past Month Use of Selected Illicit Drugs among Persons Aged 12 or Older: 2002-2010
![Page 8: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/8.jpg)
Substance Abuse Statistics
Past month illicit drug use among persons aged 12 or older by age: 2009 and 2010
![Page 9: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/9.jpg)
Substance Abuse StatisticsAlcohol Use Among Person Aged 12 or Older
• Slightly more than half of Americans aged 12 or older reported being current drinkers of alcohol in the 2010 survey (51.8%). This translates to an estimated 131.3 million people, similar to 2009, 130.6 million (51.4%)
• Nearly one quarter (23.1%) of persons aged 12 or older participated in binge drinking at least once in the 30 days prior to the survey in 2010. This translates to 58.6 million people, similar to 2009 (23.7%)
• 2010, heavy drinking was reported by 6.7% of the population aged 12 or older or 16.9 million people, similar to 2009 (6.8%)
Definitions:Current Use (past month) –at least 1 drink in the past 30 daysBinge Use- > 5 drinks on the same occasion on at least 1 day in the past 30 daysHeavy Use - > 5 drinks on the same occasion on each of 5 or more days in the past 30 days.
![Page 10: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/10.jpg)
Substance Abuse Statistics
Current binge and heavy alcohol use among person aged 12 or older by age: 2010
![Page 11: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/11.jpg)
Substance Abuse StatisticsDriving under the influence of alcohol in the past year among persons aged 12 or older: 2002-2010
![Page 12: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/12.jpg)
Substance Abuse Statistics
Driving under the influence of alcohol in the past year among persons aged 16 or older: Grouped By age: 2010
![Page 13: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/13.jpg)
What is Reasonable Suspicion?
Must be base on a reasonable belief that the employee is under the influence of alcohol or drugs on the basis of specific observations concerning the employee’s:
• Appearance• Behavior• Speech• Body odor
Before
After
![Page 14: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/14.jpg)
What is Reasonable Suspicion?
EXAMPLES:
Worsening of Personal Appearance
• dress, speech, gait, body odor
Decreased Reliability
• absences, late, sick leave, missed deadlines, etc.
Loss of Problem Solving
• Ignores problems, covers up, blames others, etc.
Decrease in Job Knowledge
• Reduced skills, needs supervisor, slow learning, etc.
![Page 15: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/15.jpg)
What is Reasonable Suspicion?
EXAMPLES (cont.):
Decrease in Productivity
• many breaks, wastes time, does not complete tasks
Poor Judgment
• bad decisions, tactless, illogical behavior, etc.
Difficulty Working with Others
• poor listening and communication skills, hostile, argumentative, etc.
![Page 16: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/16.jpg)
Signs and Symptoms of Substance Abuse
• Odor of alcohol
• Odor of marijuana
• Slurred speech
• Flushed swollen face
• Red or runny eyes or nose
• Pupils dilated or constricted or unusual eye movements
• Lack of coordination
• Tremors, sweats
• Exhaustion, fatigue
• Sleepiness
• Nausea
• Reduced concentration/focusing
• Unauthorized possession of alcohol or illegal drugs
• Any other suspicious behavior
![Page 17: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/17.jpg)
Components of a Drug Free Work Place Program
Issued by President Regan in 1986:
• Written policy regarding substance abuse
• Supervisor training
• Employee education
• Employee Assistance Program
• Methods for identifying drug users
(drug testing)
![Page 18: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/18.jpg)
Components of a Drug Free Work Place Program
Purpose of Drug Testing:
• Reduce illicit/inappropriate use of drugs among workers
• Educate workforce managers and employees
• Identify and remove drug users from safety sensitive jobs
• Treat and rehabilitate drug abusers
• Create a deterrent against drug use/abuse
![Page 19: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/19.jpg)
Components of a Drug Free Work Place Program
Types of Drug Testing:
• Pre-employment
• Post accident
• Reasonable suspicion/for cause
• Random
• Return to duty
• Follow up to treatment
• Periodic/voluntary
![Page 20: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/20.jpg)
Components of a Drug Free Work Place Program
Standards of Practice:
• Federally regulated
- DHHS
- DOT
- DOD
• Non federally regulated
- State laws
- Workers compensation
- Union Contracts
![Page 21: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/21.jpg)
Components of a Drug Free Work Place Program
Drug Testing – 3 Steps
1. Specimen Collection
2. Specimen Testing and Confirmation
3. Medical Review of Results (MRO)
Test for:
- Illicit drugs (urine)
- Alcohol (breath, saliva)
- Other specimens (oral, fluids, hair)
![Page 22: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/22.jpg)
Components of a Drug Free Work Place Program
DOT Urine Specimen Collection Procedures
1. The collector will ask the donor for photo identification
2. After verification of the donor’s identification, the collector will complete Step 1 of the Custody and Control Form (CCF)
3. The collector will ask the donor to remove any unnecessary outer clothing (coat, jacket, hat, etc.) and to leave hand carried items (i.e. briefcase, pocketbook bags, etc.) outside the toilet enclosure. The collector will secure these items and provide a receipt if requested by the donor. The donor may retain his/her wallet, money clip etc.
![Page 23: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/23.jpg)
Components of a Drug Free Work Place Program
DOT Urine Specimen Collection Procedures (cont.)
4. The collector will direct the donor to empty his/her pockets and display the contents. Any items which can be used to adulterate or substitute the specimen must be left outside the toilet enclosure. If the collector believes that any items were brought specifically with the intent to adulterate or substitute the specimen, the collector shall conduct the collection under direct observation.
5. The collector will instruct the donor to wash and dry his/her hands.
6. The collector will provide the donor a wrapped/sealed collection container and specimen bottle (s). Either the collector or the donor may open the container/bottle (s) in the donor’s presence.
![Page 24: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/24.jpg)
Components of a Drug Free Work Place Program
DOT Urine Specimen Collection Procedures (cont.)
7. The collection container and the specimen bottles must be separately wrapped. Only the collection container should be taken into the toilet enclosure. The wrapped bottles should remain outside the enclosure and be opened in the donor’s presence when the donor presents the filled collection container to the collector.
8. The collector will accompany the donor to the toilet enclosure where the donor will provide the urine specimen. The donor will enter the toilet enclosure and shut the door, the collector remains outside the close door.
9. The donor will hand the filled collection container to the collector. Both the donor and the collector should maintain visual contact of the specimen until the labels/seals are placed over the bottle cap(s).
![Page 25: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/25.jpg)
Components of a Drug Free Work Place Program
DOT Urine Specimen Collection Procedures (cont.)
10.The collector checks the specimen, reading the specimen temperature indicator within 4 minutes of receiving the specimen from the donor. The collector marks the appropriate box in Step 2 of the CCF. If the specimen temperature is outside the acceptable temperature range (90-100° F), the collector must direct the donor to provide another specimen under direct observation. The out-of-temperature-range specimen is not discarded.
11.The collector checks the specimen volume, ensuring that there is at least 45 ml. of urine. If the employee is unable to void or voids an insufficient amount of urine, the employee will be provided up to 40 oz. of fluids and up to three hours to provide the specimen. Any partial specimen will be discarded.
![Page 26: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/26.jpg)
Components of a Drug Free Work Place Program
DOT Urine Specimen Collection Procedures (cont.)
12.The collector checks the specimen for unusual color, odor, or other physical qualities that may indicate an attempt to adulterate the specimen. If present, the collector must direct the donor to provide another specimen under direct observation.
13.The collector will pour at least 30 ml of specimen into a specimen bottle (Bottle A). The remainder of the specimen (at least 15 ml) will be poured into a second bottle (Bottle B)
14.The collector immediately places the lid/cap (s) on the specimen bottles, and then applies tamper-evident label/seals (CCF, Step 3).
15.The collector will write the date on the label/seals. The donor will be asked to initial the label/seal (s) once they are affixed to the bottles.
![Page 27: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/27.jpg)
Components of a Drug Free Work Place Program
DOT Urine Specimen Collection Procedures (cont.)
16.After sealing the specimen bottles, the donor will be permitted to wash and dry his/her hands, if he/she do desires.
17.The donor will be instructed to read and complete the donor certification section of the CCS (Step 5), including signing the certification statement.
18.The collector will complete the chain of custody section of the CCF (Step 4), including signing the certification statement, recording the date and time of the collection, and entering the name of the Delivery or courier service (e.g. FedEx, DHL, USPS, LabCorp Courier).
19.The collector will record any remarks concerning the collection process in the “remarks” in Step 2 of the CCF.
![Page 28: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/28.jpg)
Components of a Drug Free Work Place Program
DOT Urine Specimen Collection Procedures (cont.)
20. The collector will place the sealed specimen bottles and Copy 1 of the CCF into the polyurethane bag and seal it. If the specimens are being transported by express or common carrier, the bag is placed in a hard-sided shipping container.
21. The collector will give the donor his/her copy of the CCF (copy 5). The donor may leave the collection site at the completion of this step of the collection process.
22. The collector will distribute the remaining copies of the custody and control form. Copy 2 should be faxed to the MRO listed in Step 1 of the CCF. Copy 3 is retained by the collector for 30 days. Copy 4 is faxed to the Designated Employer Representative (DER) listed in Step 1 of the CCF. If Copy 2 & 4 are not faxed to the MRO and DER respectively, they must be mailed or send within 24 hours or the next business day of the collection.
![Page 29: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/29.jpg)
Components of a Drug Free Work Place Program
DOT’s Direct Observation Procedures
1. DOT’s 49 CFR Part 40 directly observed collections are authorized and required when:
The employee attempts to tamper with his or her specimen at the collection site.
The specimen temperature is outside the acceptable range.
The specimen shows signs of tampering unusual color/odor/characteristic
The collector finds an item in the employee’s pockets or wallet which appears to be brought into the site to contaminate a specimen: or the collector notes conduct suggesting tampering
![Page 30: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/30.jpg)
Components of a Drug Free Work Place Program
DOT’s Direct Observation Procedures (cont.)
The Medical Review Officer (MRO) orders the direct observation because:
The employee has legitimate medical reason for certain atypical laboratory results or
The employee’s positive pr refusal (adulterated/substituted) test result had to be cancelled because the split specimen test could not be performed (for example, the split specimen was not collected).
The test is a Follow-Up test or a Return-to-Duty test.
![Page 31: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/31.jpg)
Components of a Drug Free Work Place Program
DOT’s Direct Observation Procedures (cont.)
2. The observer must be the same gender as the employee.
3. If the collector is not the observer, the collector must instruct the observer about the procedures for checking the employee for prosthetic or other devices designed to carry “clean” urine and urine substitutes AND for watching the employee urinate into the collection container. The observer requests the employee to raiser his or her shirt,
blouse or dress/skirt, as appropriate, above the waist, just above the navel, and lower clothing and underpants to mid-thigh and show the observer, by turning around, that the employee does not have such a device.
![Page 32: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/32.jpg)
Components of a Drug Free Work Place ProgramDOT’s Direct Observation Procedures (cont.)
The observer requests the employee to raiser his or her shirt, blouse or dress/skirt, as appropriate, above the waist, just above the navel, and lower clothing and underpants to mid-thigh and show the observer, by turning around, that the employee does not have such a device.
If the Employee Has a Device: The observer immediately notifies the collector; the collector stops the collection; and the collector thoroughly documents the circumstances surrounding the event in the remarks section of CCF. The collector notifies the DER. This is a refusal to test.
If the Employee Does Not Have a Device: The employee is permitted to return clothing to its proper position for the observed collection. The observer must watch the urine go from the employee’s body into the collection container. The observer must watch as the employee takes the specimen to the collector. The collector then completes the collection process.
![Page 33: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/33.jpg)
Components of a Drug Free Work Place Program
DOT’s Direct Observation Procedures (cont.)
4. Failure of the employee to permit any part of the direct observation procedure is a refusal to test.
![Page 34: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/34.jpg)
Specimen Testing and Confirmation
Goals of a Forensic Drug Testing Laboratory
To discriminate reliably between those specimens which contain drugs or its metabolite at or above the cut off and those which do not.
To determine specimen validity.
To identify specimens that are substituted or adulterated
To perform these tests in a legally defensible manner.
![Page 35: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/35.jpg)
Specimen Testing and Confirmation
Initial Test (Screening Test)
Immuno assay test which meets the FAD requirement
Negative Specimen
Any specimen whose apparent concentration of drug or metabolite is less than the pre-established cut-off concentration fore that drug or metabolite.
Not necessarily a specimen containing no drug or metabolite.
![Page 36: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/36.jpg)
Specimen Testing and Confirmation
Positive Specimen
Any specimen whose apparent concentration of drug or metabolite is greater than or equal to the pre-established cut-off concentration for that drug or metabolite
What is a Cut-Off?
An arbitrary point on a continuum of possible drug or metabolite concentrations.
Use to divide specimens into negatives and positives
![Page 37: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/37.jpg)
Specimen Testing and Confirmation
HHS Mandated Screening Cut-offs (ng/ml)
• Marijuana Metabolites 50
• Cocaine Metabolites 150
• Opiate Metabolites 2000
• PCP 25
• Amphetamines 500
![Page 38: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/38.jpg)
Specimen Testing and Confirmation
Confirmatory Test
A second analytical procedure performed on a different aliquot of the original specimen to identify an agent or the presence of a specific drug or metabolite.
Combination of gas chromatography and mass spectrometric analysis GC/MS.
![Page 39: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/39.jpg)
Specimen Testing and Confirmation
DOT Mandatory Confirmation Cut-offs (ng/ml)
• Marijuana Metabolites 15
• Cocaine Metabolites 100
• Opiate Metabolites 2000
• PCP 25
• Amphetamines 250
![Page 40: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/40.jpg)
Specimen Testing and Confirmation
Validity Testing
Specimen validity testing is the evaluation of the specimen to determine if it is consistent with normal human urine.
The purpose of validity testing is to determine whether certain adulterants or foreign substances were added to the urine, if the urine was diluted, or if the specimen was substituted.
![Page 41: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/41.jpg)
Broad MRO Role In DOT Testing
MRO is the “gatekeeper” of testing process.
Responsible for review of custody and control form for errors (negatives & positives).
Must notify collector or employer when error causes cancellation of test results
Must offer to interview donor with Positive, Adulterated, Substituted and Invalid test results.
Must review “shy bladder” medical findings
Must report medical information to employer when safety or medical qualification is an issue
![Page 42: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/42.jpg)
Broad MRO Role In DOT Testing
1. Receive Results
2. Review Results
3. Interview
4. Record Pertinent Findings
5. Revel (in donor explanations)
6. Reconfirm split sample
7. Refer for Medical Evaluation
8. Interpret Findings
9. Report to Employer
10.Release Medical Information
11.Record Keep
MRO Responsibilities in Regulated Testing (9 R’s; 2 I’s)
![Page 43: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/43.jpg)
Broad MRO Role In DOT Testing
Laboratory Reporting to MRO
All test results come from lab to MRO
Cannot go to TPA or employer
Negative results can be emailed without a CCF copy
Lab must report quantitative results on all positive results
Rejected for testing, adulterated and substituted results must include standard explanatory remarks
![Page 44: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/44.jpg)
Broad MRO Role In DOT Testing
MRO Review of Lab Negative Results
Review lab results (electronic or CCF)
Review CCF copy 2 for flaws
Check negative on CCF copy 2
MRO staff can conduct review and use signature stamp
MRP must personally review and sign 5% of negatives
![Page 45: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/45.jpg)
Broad MRO Role In DOT Testing
MRO Review of Lab Non-negative Results
Non-negative result
Positive adulterated, substituted and invalid
Must have CCF copy 1 with lab scientist’s signature
Review CCF copy 2
Contact and interview donor
![Page 46: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/46.jpg)
Broad MRO Role In DOT Testing
MRO Donor Contact Process
MRO must document 3 attempts spaced over 24 hours to contact donor.
After above request, DER to contact donor
DER must document 3 attempts in 24 hours
No part of donor interview may be conducted by MRO staff
![Page 47: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/47.jpg)
Broad MRO Role In DOT Testing
The Medical Review Interview
Use standard check list form
Identify self and affiliation
Confirm identity of donor
Explain verification process
Inquire regarding illicit drug use
Inquire regarding Rx/OTC drug use and diet
Donor has 5 days to provide medical use documentation
If there is a legitimate medical explanation, the test is reported as negative
![Page 48: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/48.jpg)
Broad MRO Role In DOT Testing
MRO Results Reporting
MRO must review CCF copy 2 before reporting any DOT test results
Negative results may be transmitted electronically
Non-negative results must have MRO’s signature
MRO Record Keeping
Must maintain all CCF copy 2 with signature or stamps with initials
Negatives – 1 year
Non-negatives – 5 years
Drug test results should be separated from patient medical chart because of confidentiality concerns.
![Page 49: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/49.jpg)
Broad MRO Role In DOT Testing
MRO’s and Medical Confidentiality
MRO’s are required to release medical information to third party (employer physician, etc.) if the information is:
1) Likely to result in disqualification or
2) Continued performance of the employee’s safety sensitive functions likely poses a significant safety risk
![Page 50: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/50.jpg)
Differences Between DOT & Non-DOT Drug Testing
Tests for additional drugs beyond the 5 drug panel used in DOT
Tests are different (usually lower) cut-offs than the DOT
Single specimen tests rather than split specimen tests
Use of test specimens other than urine
Collection of prescription medication information at the time of specimen collection
Immediate removal of workers from duty pending review by the MRO if they have lab positive results.
![Page 51: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/51.jpg)
Alcohol Testing
No Direct MRO Involvement
Trained Technicians Perform Test: BAT or STT
Alcohol Testing Forms
Standard DOT form (3 copies)
Alcohol Testing Procedures Screening
Use EBT or ASD
Obtain breath or saliva sample
Result < 0.02 is negative
Result ≥ 0.02 requires confirmation test
![Page 52: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/52.jpg)
Alcohol Testing
Alcohol Testing Procedures Confirmation
Obtain breath sample
Result < 0.02 is negative
Result 0.02 – 0.039 employee cannot perform safety sensitive functions
Result ≥ 0.04 is a violation of rule
Results ≥ 0.02 immediately reported to DER
3 copies of printed results
![Page 53: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/53.jpg)
Alternative Specimens
Hair
Use for pre-employment and random
Grows at 1 cm/month or 0.3 mm/day
Oral Fluid and Sweat
Rarely used
Disadvantages
Variation in detection windows
Pharmacology not well known
More expensive
Proficiency testing programs – difficult to establish
![Page 54: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/54.jpg)
Cases
Case #1: Mr. A is an 18 year old male who comes in for pre-employment drug screen which comes back positive for methamphetamines, amphetamines, marijuana, and cocaine. On MRO review, he offers no medical explanation. He states he was at a “party” where there was a bucket and everyone who came in was pouring a lot of “stuff” into it, mixing it all. He drank from it and felt very “fuzzy”. He knew it was a “stupid” thing to do.
Result: Positive for methamphetamines, amphetamines, cocaine, and marijuana.
![Page 55: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/55.jpg)
CasesCase # 2: Mr. B is a 52 year old plumber who came in for pre-
employment drug screen which came back positive for THC. On MRO review, he stated he had a medical prescription for Dronabinol 2.5mg capsules prescribed for appetite stimulation. He brought in his medication. We confirmed his prescription use via “CURES”.
Result: Negative drug screen, however, employer was alerted to be cautious in having him perform “safety sensitive” jobs.
![Page 56: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/56.jpg)
Cases
Case # 3: Mr. C is a 33 year old male who was sent for random drug screen which was positive for cocaine. On MRO review, he stated that he had a “bad tooth” which was extracted and he couldn’t bear the pain so his friend suggested he put some “powdered cocaine” on the area to help with the pain
Result: Positive for cocaine.
![Page 57: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/57.jpg)
Cases
Case # 4: Mr. D. Is a 36 year old male who came in for post-accident drug screen which was positive for THC. On MRO review, he stated he never inhaled or ingested marijuana. However, his room mates smoked it causing his positive drug screen.
Result: Positive for THC
![Page 58: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/58.jpg)
Cases
Case # 5: Ms. E is a 28 year old female who came in for pre-employment drug screen who was positive for THC. On MRO review, she stated she had a “cannabis card” for insomnia and anxiety. Her employer however had a strict “drug free work place policy.”
Result: Positive for THC
![Page 59: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/59.jpg)
Cases
Case # 6: MR. F is a 22 year old male send in for pre-employment drug screen which was positive for amphetamines. On MRO review, he was prescribed (confirmed by me) Adderall for ADHD.
Result: Negative drug screen.
![Page 60: Drug Testing in the Workplace](https://reader035.fdocuments.in/reader035/viewer/2022062222/56814eb5550346895dbc5d6b/html5/thumbnails/60.jpg)
Thank you!
For Additional Resources, go to:
https://nsduhweb.rti.org/
http://www.dot.gov/odapc/employer.html
http://www.dot.gov/odapc/mro.html
Or contact Dr. Ramesh
(408) 228-8400